Jay R. Venkatesan - 28 Jun 2024 Form 4/A - Amendment Insider Report for Elicio Therapeutics, Inc. (ELTX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELTX	Common Warrants	Purchase	$0	+50,000		$0.000000	50,000	28 Jun 2024	Common Stock	50,000	$5.00	Direct	F1, F2, F3
transaction	ELTX	Pre-Funded Warrants	Purchase	$249,500	+50,000		$4.99	50,000	28 Jun 2024	Common Stock	50,000	$0.0100	Direct	F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
F2	The Common Warrants expire on July 1, 2029.
F3	On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein.
F4	Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
F5	The Pre-Funded Warrants do not have an expiration date.